Loading
Staining tumour samples from 144 men showed that the 40% who had lost a particular protein lived about seven months less on abiraterone.
Men who had received abiraterone and had hormone-sensitive or castration-resistant prostate cancer tissue available for PTEN immunohistochemistry were identified retrospectively, with overall survival from the start of abiraterone as the primary endpoint. One hundred and forty-four men who had received abiraterone after docetaxel had available tumour tissue. Loss of PTEN expression was observed in 40%. Matched hormone-sensitive and castration-resistant tumour biopsies were available for 41 men, and PTEN status in castration-resistant tissue matched the hormone-sensitive tissue in 86% of those cases. Loss of PTEN expression was associated with shorter median overall survival, 14 against 21 months, hazard ratio 1.75, and shorter median duration of abiraterone treatment, 24 against 28 weeks, hazard ratio 1.6. PTEN protein loss, high lactate dehydrogenase and visceral metastases were independent prognostic factors on multivariable analysis.
It made PTEN a protein test rather than a genomic one in this disease, and the concordance between early and late biopsies is the practical point: the diagnostic block usually answers the question, so a fresh biopsy is not needed to make this call.
Shares PTEN alteration (sequencing) and PTEN loss (IHC), PTEN, AKT, Androgen receptor signalling.
Shares PTEN alteration (sequencing) and PTEN loss (IHC), PTEN, AKT, Androgen receptor signalling.
Shares PTEN, Castration-resistant prostate cancer (CRPC), PI3K / AKT / mTOR, Immunohistochemistry (IHC).
Shares Androgen receptor signalling, Castration-resistant prostate cancer (CRPC), Drug resistance (primary and acquired), Histopathology & immunohistochemistry.
Shares PTEN alteration (sequencing) and PTEN loss (IHC), PTEN, AKT, PI3K / AKT / mTOR.
Shares Androgen receptor signalling, Castration-resistant prostate cancer (CRPC), Drug resistance (primary and acquired), Metastatic castration-resistant prostate cancer.
Shares Androgen receptor signalling, Castration-resistant prostate cancer (CRPC), Drug resistance (primary and acquired), Metastatic castration-resistant prostate cancer.
Shares PTEN, Androgen receptor signalling, Castration-resistant prostate cancer (CRPC), PI3K / AKT / mTOR.